NASDAQ:NLNK - NewLink Genetics Stock Price, Price Target & More

$4.68 +0.14 (+3.08 %)
(As of 04/24/2018 01:54 PM ET)
Previous Close$4.54
Today's Range$4.45 - $4.73
52-Week Range$3.75 - $19.47
Volume509,936 shs
Average Volume1.12 million shs
Market Capitalization$166.83 million
P/E Ratio-2.02
Dividend YieldN/A
Beta1.22

About NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics logoNewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NLNK
CUSIP65151110
Phone515-296-5555

Debt

Debt-to-Equity RatioN/A
Current Ratio7.96%
Quick Ratio7.96%

Price-To-Earnings

Trailing P/E Ratio-2.02
Forward P/E Ratio-2.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$28.71 million
Price / Sales6.06
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book1.14

Profitability

EPS (Most Recent Fiscal Year)($2.30)
Net Income$-71,950,000.00
Net Margins-250.60%
Return on Equity-60.60%
Return on Assets-47.48%

Miscellaneous

Employees76
Outstanding Shares37,160,000

How to Become a New Pot Stock Millionaire

NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its earnings results on Thursday, March, 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.32. The biotechnology company earned $10.10 million during the quarter, compared to the consensus estimate of $2.72 million. NewLink Genetics had a negative net margin of 250.60% and a negative return on equity of 60.60%. View NewLink Genetics' Earnings History.

When is NewLink Genetics' next earnings date?

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for NewLink Genetics.

What price target have analysts set for NLNK?

6 Wall Street analysts have issued 1 year price objectives for NewLink Genetics' stock. Their predictions range from $5.00 to $25.00. On average, they expect NewLink Genetics' stock price to reach $13.50 in the next year. View Analyst Ratings for NewLink Genetics.

What are Wall Street analysts saying about NewLink Genetics stock?

Here are some recent quotes from research analysts about NewLink Genetics stock:
  • 1. Cantor Fitzgerald analysts commented, "Data from a Phase I study of indoximod in diffuse intrinsic pontine glioma (DIPG) presented at AACR were positive, in our view, but given the recent failure of Incyte’s (INCY, NC) epacadostat, we do not believe that is likely to sway investors at this point." (4/16/2018)
  • 2. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (1/4/2018)

Who are some of NewLink Genetics' key competitors?

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the folowing people:
  • Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer (Age 56)
  • Nicholas N. Vahanian M.D., President (Age 47)
  • John Bell Henneman III, Chief Financial Officer, Secretary (Age 55)
  • Eugene P. Kennedy M.D., Chief Medical Officer (Age 49)
  • Brian Wiley, Chief Commercial Officer (Age 48)
  • Thomas A. Raffin M.D., Lead Independent Director (Age 68)
  • Paolo Pucci, Director (Age 56)
  • Paul R. Edick, Independent Director (Age 62)
  • Ernest J. Talarico III, Independent Director (Age 44)
  • Lota S. Zoth CPA, Independent Director (Age 57)

Has NewLink Genetics been receiving favorable news coverage?

News coverage about NLNK stock has trended somewhat positive on Tuesday, according to Accern. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NewLink Genetics earned a media sentiment score of 0.03 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.08 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of NewLink Genetics?

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $4.68.

How big of a company is NewLink Genetics?

NewLink Genetics has a market capitalization of $166.83 million and generates $28.71 million in revenue each year. The biotechnology company earns $-71,950,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. NewLink Genetics employs 76 workers across the globe.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE SUITE 5100, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]


MarketBeat Community Rating for NewLink Genetics (NLNK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  476
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NewLink Genetics (NASDAQ:NLNK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for NewLink Genetics in the last 12 months. Their average twelve-month price target is $13.50, suggesting that the stock has a possible upside of 188.46%. The high price target for NLNK is $25.00 and the low price target for NLNK is $5.00. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.173.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.50$23.6667$25.6667$25.8333
Price Target Upside: 188.46% upside211.81% upside203.57% upside129.63% upside

NewLink Genetics (NASDAQ:NLNK) Consensus Price Target History

Price Target History for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ:NLNK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018Cantor FitzgeraldSet Price TargetHold$7.00HighView Rating Details
4/12/2018Jefferies GroupReiterated RatingHoldHighView Rating Details
4/9/2018Robert W. BairdDowngradeOutperform -> Neutral$22.00 -> $5.00HighView Rating Details
4/6/2018Bank of AmericaDowngradeBuy -> NeutralHighView Rating Details
4/6/2018SunTrust BanksDowngradeBuy -> Hold$19.00 -> $5.00HighView Rating Details
3/2/2018Stifel NicolausReiterated RatingBuy$25.00 -> $21.00HighView Rating Details
5/10/2016MizuhoLower Price TargetBuy$52.00 -> $20.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

NewLink Genetics (NASDAQ:NLNK) Earnings History and Estimates Chart

Earnings by Quarter for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ:NLNK) Earnings Estimates

2018 EPS Consensus Estimate: ($2.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.63)($0.51)($0.57)
Q2 20181($0.66)($0.66)($0.66)
Q3 20182($0.69)($0.62)($0.66)
Q4 20181($0.63)($0.63)($0.63)

NewLink Genetics (NASDAQ NLNK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018($0.55)N/AView Earnings Details
3/1/2018Q4 2017($0.69)($0.37)$2.72 million$10.10 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.74)($0.69)$2.38 million$5.48 millionViewN/AView Earnings Details
7/28/2017Q2 2017($0.78)($0.5720)$2.65 million$10.37 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.82)($0.72)$2.68 million$2.76 millionViewListenView Earnings Details
2/28/2017Q416($0.66)($0.4630)$4.31 million$12.70 millionViewListenView Earnings Details
11/1/2016Q3($0.60)($0.54)$3.83 million$15.35 millionViewN/AView Earnings Details
7/29/2016Q216($0.77)($1.12)$4.81 million$2.01 millionViewListenView Earnings Details
4/29/2016Q116($1.70)($0.82)$2.08 million$4.34 millionViewListenView Earnings Details
2/29/2016Q415($0.92)($0.75)$4.89 million$6.06 millionViewListenView Earnings Details
11/3/2015Q315($0.66)($0.55)$9.01 million$14.21 millionViewN/AView Earnings Details
7/31/2015Q215($0.70)($0.49)$4.32 million$7.45 millionViewListenView Earnings Details
5/5/2015Q115($0.22)$0.35$12.78 million$39.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.78)$4.05$2.98 million$159.25 millionViewN/AView Earnings Details
11/6/2014Q314($0.41)($0.20)$0.31 million$2.80 millionViewN/AView Earnings Details
8/5/2014Q214($0.42)($0.33)$0.30 million$0.21 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.37)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
3/11/2014($0.37)($0.31)$0.33 million$0.29 millionViewN/AView Earnings Details
11/11/2013Q3($0.3250)($0.32)$0.33 million$0.27 millionViewN/AView Earnings Details
8/7/2013Q213($0.32)($0.28)$0.59 million$0.2320 millionViewN/AView Earnings Details
5/6/2013Q113($0.28)($0.33)$0.41 million$0.3020 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.33)($0.30)ViewN/AView Earnings Details
10/31/2012Q3 2012($0.32)($0.28)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.31)($0.31)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.36)($0.24)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.36)($0.44)ViewN/AView Earnings Details
12/16/2011Q3 2011($1.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NewLink Genetics (NASDAQ:NLNK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NewLink Genetics (NASDAQ NLNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.30%
Institutional Ownership Percentage: 65.00%
Insider Trading History for NewLink Genetics (NASDAQ:NLNK)
Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ NLNK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Carl W. LangrenInsiderSell2,229$9.05$20,172.45View SEC Filing  
10/6/2017Stine Seed Farm, Inc.Major ShareholderBuy780,487$10.25$7,999,991.757,857,732View SEC Filing  
3/15/2016Charles J Jr. LinkCEOSell25,000$17.86$446,500.00297,756View SEC Filing  
1/6/2016Charles J. Jr. LinkCEOSell25,000$32.53$813,250.00342,756View SEC Filing  
1/5/2016Brian WileyVPSell1,295$34.99$45,312.0519,942View SEC Filing  
1/5/2016Carl W. LangreninsiderSell1,095$34.97$38,292.1513,465View SEC Filing  
1/5/2016Charles J. Jr. LinkCEOSell5,001$35.06$175,335.06342,756View SEC Filing  
1/5/2016John B. Henneman IIICFOSell175$35.74$6,254.5062,316View SEC Filing  
10/7/2015Charles J. Jr. LinkCEOSell10,000$35.16$351,600.00371,118View SEC Filing  
10/5/2015Charles J. Jr. LinkCEOSell15,000$37.36$560,400.00371,118View SEC Filing  
7/13/2015Joseph SaluriDirectorSell5,000$50.42$252,100.00View SEC Filing  
7/6/2015Charles J Jr. LinkCEOSell20,000$44.65$893,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NewLink Genetics (NASDAQ NLNK) News Headlines

Source:
DateHeadline
NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018
finance.yahoo.com - April 20 at 5:21 PM
NewLink Genetics (NLNK) Downgraded to Sell at Zacks Investment ResearchNewLink Genetics (NLNK) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 8:34 PM
NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster PresentationNewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation
finance.yahoo.com - April 17 at 5:54 PM
Zacks: Analysts Expect NewLink Genetics Corp (NLNK) Will Post Quarterly Sales of $5.78 MillionZacks: Analysts Expect NewLink Genetics Corp (NLNK) Will Post Quarterly Sales of $5.78 Million
www.americanbankingnews.com - April 17 at 1:50 AM
NewLink down 8% after bailing on indoximod in melanoma studyNewLink down 8% after bailing on indoximod in melanoma study
seekingalpha.com - April 16 at 5:24 PM
Early data indicate indoximod has clinical activity when used in combination therapies beyond PD-1 inhibitionEarly data indicate indoximod has clinical activity when used in combination therapies beyond PD-1 inhibition
globenewswire.com - April 16 at 8:16 AM
NewLink Genetics (NLNK) Hold Rating Reaffirmed at Cantor FitzgeraldNewLink Genetics' (NLNK) Hold Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 16 at 7:11 AM
 Analysts Anticipate NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share Analysts Anticipate NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 15 at 11:10 PM
NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy forNewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for
www.nasdaq.com - April 15 at 6:35 PM
Jefferies Group Reiterates "Hold" Rating for NewLink Genetics (NLNK)Jefferies Group Reiterates "Hold" Rating for NewLink Genetics (NLNK)
www.americanbankingnews.com - April 12 at 11:17 AM
NewLink Genetics Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In DowngradeNewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade
finance.yahoo.com - April 10 at 8:27 AM
NewLink Shares Plunge After Incyte & Merck's Study FailsNewLink Shares Plunge After Incyte & Merck's Study Fails
finance.yahoo.com - April 10 at 8:27 AM
New Research Coverage Highlights Golden Star Resources, Ryanair, Sasol, Access National, NewLink Genetics, and Canadian Pacific Railway — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Golden Star Resources, Ryanair, Sasol, Access National, NewLink Genetics, and Canadian Pacific Railway — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - April 10 at 8:27 AM
NewLink Shares Plunge After Incyte & Mercks Study FailsNewLink Shares Plunge After Incyte & Merck's Study Fails
www.zacks.com - April 9 at 5:21 PM
UPDATE: Baird Downgrades NewLink Genetics (NLNK) to Neutral Citing IDO ConcernsUPDATE: Baird Downgrades NewLink Genetics (NLNK) to Neutral Citing IDO Concerns
www.streetinsider.com - April 9 at 5:21 PM
UPDATE: Cantor Fitzgerald Downgrades NewLink Genetics (NLNK) to NeutralUPDATE: Cantor Fitzgerald Downgrades NewLink Genetics (NLNK) to Neutral
www.streetinsider.com - April 9 at 5:21 PM
NewLink Genetics (NLNK) Rating Lowered to Hold at Robert W. BairdNewLink Genetics (NLNK) Rating Lowered to Hold at Robert W. Baird
www.americanbankingnews.com - April 9 at 7:55 AM
NewLink Genetics (NLNK) Lowered to "Hold" at Cantor FitzgeraldNewLink Genetics (NLNK) Lowered to "Hold" at Cantor Fitzgerald
www.americanbankingnews.com - April 9 at 7:55 AM
SunTrust Robinson Humphrey Downgrades NewLink Genetics (NLNK) to HoldSunTrust Robinson Humphrey Downgrades NewLink Genetics (NLNK) to Hold
www.streetinsider.com - April 7 at 8:25 AM
NewLink Genetics (NLNK) Downgraded by Jefferies Group to "Hold"NewLink Genetics (NLNK) Downgraded by Jefferies Group to "Hold"
www.americanbankingnews.com - April 6 at 9:16 PM
NewLink Genetics shares plummet 39% after Merck, Incyte trial failureNewLink Genetics shares plummet 39% after Merck, Incyte trial failure
www.marketwatch.com - April 6 at 5:41 PM
Incytes late-stage epacadostat flop pressures NewLink Genetics, down 32% premarketIncyte's late-stage epacadostat flop pressures NewLink Genetics, down 32% premarket
seekingalpha.com - April 6 at 5:41 PM
NewLink Genetics Announces Review of Clinical ProgramsNewLink Genetics Announces Review of Clinical Programs
www.nasdaq.com - April 6 at 5:41 PM
Why Incyte and NewLink Genetics Crashed TodayWhy Incyte and NewLink Genetics Crashed Today
finance.yahoo.com - April 6 at 5:41 PM
NewLink Genetics (NLNK) Lowered to "Neutral" at Bank of AmericaNewLink Genetics (NLNK) Lowered to "Neutral" at Bank of America
www.americanbankingnews.com - April 6 at 4:14 PM
SunTrust Banks Downgrades NewLink Genetics (NLNK) to HoldSunTrust Banks Downgrades NewLink Genetics (NLNK) to Hold
www.americanbankingnews.com - April 6 at 1:23 PM
Cantor Fitzgerald Analysts Give NewLink Genetics (NLNK) a $26.00 Price TargetCantor Fitzgerald Analysts Give NewLink Genetics (NLNK) a $26.00 Price Target
www.americanbankingnews.com - April 6 at 12:11 PM
Technical Perspectives on Biotech Stocks -- Neptune Technologies & Bioressources, Neuralstem, NewLink Genetics, and OHR PharmaTechnical Perspectives on Biotech Stocks -- Neptune Technologies & Bioressources, Neuralstem, NewLink Genetics, and OHR Pharma
www.prnewswire.com - April 5 at 6:27 AM
NewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences ConferenceNewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 3 at 5:35 PM
NewLink Genetics (NLNK) Upgraded to Buy by Zacks Investment ResearchNewLink Genetics (NLNK) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 1 at 5:22 PM
NewLink Genetics Corp (NLNK) Given Consensus Recommendation of "Buy" by AnalystsNewLink Genetics Corp (NLNK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 1 at 1:30 PM
Zacks Investment Research Downgrades NewLink Genetics (NLNK) to HoldZacks Investment Research Downgrades NewLink Genetics (NLNK) to Hold
www.americanbankingnews.com - April 1 at 12:58 PM
$5.78 Million in Sales Expected for NewLink Genetics Corp (NLNK) This Quarter$5.78 Million in Sales Expected for NewLink Genetics Corp (NLNK) This Quarter
www.americanbankingnews.com - April 1 at 5:51 AM
NewLink Genetics (NLNK) PT Set at $26.00 by Cantor FitzgeraldNewLink Genetics (NLNK) PT Set at $26.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 12:05 PM
NewLink Genetics Target of Unusually High Options Trading (NLNK)NewLink Genetics Target of Unusually High Options Trading (NLNK)
www.americanbankingnews.com - March 30 at 7:06 AM
-$0.55 EPS Expected for NewLink Genetics Corp (NLNK) This Quarter-$0.55 EPS Expected for NewLink Genetics Corp (NLNK) This Quarter
www.americanbankingnews.com - March 30 at 3:22 AM
Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock March 29, 2018Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock March 29, 2018
www.zacks.com - March 29 at 5:30 PM
NewLink Genetics (NLNK) Names Chad A. Johnson to Board - StreetInsider.comNewLink Genetics (NLNK) Names Chad A. Johnson to Board - StreetInsider.com
www.streetinsider.com - March 23 at 8:19 AM
NewLink Genetics Appoints Chad A. Johnson to Board of Directors - GlobeNewswire (press release)NewLink Genetics Appoints Chad A. Johnson to Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 22 at 8:26 AM
NewLink Genetics Appoints Chad A. Johnson to Board of DirectorsNewLink Genetics Appoints Chad A. Johnson to Board of Directors
finance.yahoo.com - March 21 at 5:37 PM
NewLink Genetics Announces Presentation of Abstracts at AACR ... - GlobeNewswire (press release)NewLink Genetics Announces Presentation of Abstracts at AACR ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:17 AM
Factors of Influence in 2018, Key Indicators and Opportunity within NewLink Genetics, Chipmos Technologies, Helen of Troy, InterDigital, Summit Therapeutics, and Kornit Digital — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within NewLink Genetics, Chipmos Technologies, Helen of Troy, InterDigital, Summit Therapeutics, and Kornit Digital — New Research Emphasizes Economic Growth
finance.yahoo.com - March 15 at 8:17 AM
NewLink Genetics Announces Presentation of Abstracts at AACR Annual MeetingNewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
finance.yahoo.com - March 14 at 7:06 PM
NewLink Genetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)NewLink Genetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:26 AM
 Analysts Expect NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share Analysts Expect NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - March 12 at 11:06 PM
Stock Traders Purchase Large Volume of NewLink Genetics Put Options (NLNK)Stock Traders Purchase Large Volume of NewLink Genetics Put Options (NLNK)
www.americanbankingnews.com - March 8 at 8:14 AM
NewLink Genetics Corp (NLNK) Receives Consensus Recommendation of "Buy" from AnalystsNewLink Genetics Corp (NLNK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 7 at 1:51 PM
FY2018 Earnings Estimate for NewLink Genetics Corp (NLNK) Issued By Cantor FitzgeraldFY2018 Earnings Estimate for NewLink Genetics Corp (NLNK) Issued By Cantor Fitzgerald
www.americanbankingnews.com - March 7 at 11:53 AM
NewLink Genetics Corp (NLNK) Expected to Earn Q1 2018 Earnings of ($0.51) Per ShareNewLink Genetics Corp (NLNK) Expected to Earn Q1 2018 Earnings of ($0.51) Per Share
www.americanbankingnews.com - March 5 at 1:48 AM
Hudson Bay Capital Management LP Purchases New Holdings in NewLink Genetics Corp (NLNK)Hudson Bay Capital Management LP Purchases New Holdings in NewLink Genetics Corp (NLNK)
www.americanbankingnews.com - March 3 at 12:51 PM

SEC Filings

NewLink Genetics (NASDAQ:NLNK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NewLink Genetics (NASDAQ:NLNK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NewLink Genetics (NASDAQ NLNK) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.